Provided by Tiger Trade Technology Pte. Ltd.

Arcutis Biotherapeutics Inc.

26.58
+2.098.53%
Post-market: 26.45-0.1300-0.49%19:47 EDT
Volume:1.73M
Turnover:45.46M
Market Cap:3.32B
PE:123.39
High:26.97
Open:24.50
Low:24.30
Close:24.49
52wk High:31.77
52wk Low:19.30
Shares:125.07M
Float Shares:111.18M
Volume Ratio:0.79
T/O Rate:1.56%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.2154
EPS(LYR):-0.1269
ROE:15.86%
ROA:5.09%
PB:15.07
PE(LYR):-209.52

Loading ...

Arcutis Biotherapeutics Director Christopher Peetz Files Initial Beneficial Ownership Statement

Reuters
·
Jul 18

Arcutis Biotherapeutics Director Howard G. Welgus Disposes of 4,730 Common Shares Worth $127,269.30

Reuters
·
Jul 18

Arcutis Appoints Mirum CEO Chris Peetz to Board

Reuters
·
Jul 16

Arcutis Expands Board of Directors with Appointment of Chris Peetz

THOMSON REUTERS
·
Jul 16

Arcutis Biotherapeutics Schedules Second-quarter Results Conference Call

Reuters
·
Jul 16

Attovia Therapeutics Appoints John W. Smither to Board of Directors

THOMSON REUTERS
·
Jul 15

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jul 15

MBX Biosciences Names Steve Hoerter CEO, Replacing Kent Hawryluk

Reuters
·
Jul 14

Arcutis Biotherapeutics (ARQT) Receives a Buy from Jefferies

TIPRANKS
·
Jul 09

Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT) and Seres Therapeutics (MCRB)

TIPRANKS
·
Jul 09

Arcutis Biotherapeutics Says FDA Accepted ZORYVE Expansion Filing for Infants With Eczema

MT Newswires Live
·
Jul 08

Arcutis Biotherapeutics announces FDA acceptance of Zoryve sNDA

TIPRANKS
·
Jul 08

FDA Accepts Arcutis Snda for Zoryve Cream Use in Infants with Atopic Dermatitis

Reuters
·
Jul 08

Arcutis Biotherapeutics - FDA Sets Pdufa Target Action Date of February 23, 2027 for Zoryve Cream 0.05% Snda

THOMSON REUTERS
·
Jul 08

FDA Accepts Supplemental New Drug Application for Arcutis’ Zoryve® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months

THOMSON REUTERS
·
Jul 08

Arcutis Grants 61,000 Rsus to Nine New Hires Under 2022 Inducement Plan

Reuters
·
Jul 03

Arcutis Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Jul 03

Arcutis Biotherapeutics - Launches Virtual Health Platform to Expand Access to Zoryve Portfolio

THOMSON REUTERS
·
Jun 30

Arcutis Biotherapeutics Wins FDA Approval For Expanded Pediatric Skin Drug Use

MT Newswires Live
·
Jun 30

FDA approves supplemental NDA to expand indication of Arcutis’ Zoryve cream

TIPRANKS
·
Jun 30